Industry Insights

Industry Targeted Insight

Our Commitment to Providing Value

PayerAlly is dedicated to providing our clients with a wealth of resources that keep them up-to-date on the latest industry news through our white papers, comprehensive webinars, and the work of industry thought leaders. The pharmaceutical landscape is always experiencing new challenges and changes, and our promise to you is that we consistently deliver innovative solutions that keep up with the industry's ever-changing nature.

All Articles
  • All Articles
  • Industry Insights
  • Medication Updates

Gene Therapy – “Therapy” Not Medication

Industry Insights A white paper on understanding gene therapy What is Gene Therapy? Gene therapy is all the BUZZ in conversations about medication cost control and yet it is not a medication. So what is gene therapy and what makes it different than the ‘medications’ of the past. Why should we as stewards of health…

Manufacturer Funding – The Ups & Downs

Industry Insights A white paper on manufacturer funding Why is manufacturer subsidized funding a ‘big deal’? There has been a great deal of commentary on manufacturer funding, and how plans are using the funding to do more to offset patient cost share amounts. In this white paper, we are going to give you the background…

New SGLT2 inhibitor for Diabetes Type 2 | Brenzavvy

Industry Insights Medication Update New SGLT2 inhibitor for Diabetes Type 2 On January 23, 2023, the FDA approved Brenzavvy (bexagliflozin) made by TheracosBio for the treatment of adults with type 2 diabetes.1 Brenzavvy is a SGLT2 inhibitor that lowers blood sugar by causing the removal of sugar from the body through urine.Brenzavvy is available as 20…

The Ins and Outs of PBM Audit

Industry Insights A white paper on pharmacy audit & investigations Understanding your audit and investigative program – is it working for you? In many cases, we see our audit and investigative reports and check a box that our vendors are managing the network and preventing Fraud, Waste, and Abuse (FWA). Running a tight network audit…

First biosimilar for Humira® now available | Amjevita™

Industry Insights Medication Update First biosimilar for Humira® now available Availability of Amjevita™, the first biosimilar for Humira®, rocked the headlines on January 31, 2023. Amjevita™ (adalimumab-atto), a citrate-free biosimilar to Humira® (adalimumab), is now available in the U.S.1Similar to the Humira, Amjevita carries all the same indications for:2 Rheumatoid arthritis (RA) Juvenile idiopathic arthritis…

Administrative Fees or Percent of Value

Industry Insights A brief discussion on paying for medication management services Do Vendor Payment Models Support a Drive to Lowest Net Cost? In many cases, we see our audit and investigative reports and check a box that our vendors are managing the network and preventing Fraud, Waste, and Abuse (FWA). Running a tight network audit…

Connect With Us Today

PayerAlly is proud to offer our clients high-quality, expert consulting and PBM services in procurement, PBM monitor program, PBM audits, PBM benchmarking, pharmaceutical strategy consulting, clinical program development, market research, and PBM implementation management services. Reach out to us today so one of our team members can get back to you promptly.

Need help?

PayerAlly’s mission is to provide pharmacy consulting services to our clients in an impartial manner enabling them to make better decisions, lower overall medication costs, and better plan for future high-cost, life-changing medications.